Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term prophylaxis in bipolar disorder.

Matthew J Taylor1, Guy M Goodwin

  • 1Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.

CNS Drugs
|April 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modelling health-based place of safety capacity.

The British journal of psychiatry : the journal of mental science·2026
Same author

Affective Instability and Regular Cannabis Use During Adolescence and Subsequent Risk for Psychosis in Early Adulthood: A Longitudinal Birth Cohort Study.

Schizophrenia bulletin open·2026
Same author

TDP-43 related amyotrophic lateral sclerosis-frontotemporal dementia and links to the DNA damage response: a systematic review and narrative synthesis.

Frontiers in molecular neuroscience·2026
Same author

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Journal of affective disorders·2026
Same author

A digital imagery-competing task intervention for stopping intrusive memories in trauma-exposed health-care staff during the COVID-19 pandemic in the UK: a Bayesian adaptive randomised clinical trial.

The lancet. Psychiatry·2026
Same author

Dose-dependent pharmacological mechanisms within the Neuroscience-based Nomenclature: a new concept to facilitate neuroscience-based prescribing.

The lancet. Psychiatry·2026
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Preventing relapse in bipolar disorder is crucial. This review covers evidence for medications like lithium and valproate, and strategies to enhance clinical care for long-term management.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Bipolar disorder is a significant cause of disability, with relapse prevention being a primary management objective.
  • Long-term management relies heavily on pharmacological interventions integrated with enhanced clinical care.

Purpose of the Study:

  • To summarize evidence for pharmacological options in bipolar disorder management.
  • To provide guidance on clinical issues aligned with current practice guidelines.

Main Methods:

  • Review of evidence from randomized trials for various pharmacological agents.
  • Analysis of treatment adherence, stressor management, and psychological interventions.

Main Results:

  • Long-term prophylaxis with agents like lithium, valproate, lamotrigine, and olanzapine is recommended for bipolar I disorder.

Related Experiment Videos

  • Medications vary in their efficacy against manic versus depressive relapse.
  • Combination treatments show potential for enhanced efficacy.

    • Conclusions:

    • Consider long-term prophylaxis for all patients with bipolar I disorder.
    • Enhance clinical care through education, adherence strategies, and stress management.
    • Gradual dose tapering is advised upon discontinuation of prophylaxis.